Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN II 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Aminosyn II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis when administered intravenously. It serves as a substrate for protein metabolism, promoting nitrogen retention and tissue repair.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
Intravenous infusion, typical adult dose is 1.0 to 1.5 g amino acids/kg/day, administered as part of total parenteral nutrition; rate not to exceed 0.1 g amino acids/kg/hour.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
Variable; individual amino acids have half-lives ranging from minutes to hours. Clinical context: infusion rate and metabolic demand determine steady-state levels.
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Amino acids are primarily eliminated via metabolism; less than 10% is excreted renally as free amino acids. No significant biliary or fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution